Mbiotech to distribute Gene Bridges Recombineering Technology in Korea

Heidelberg, February 19, 2008 - Gene Bridges GmbH, the recombineering company, announced that Mbiotech will distribute Gene Bridges’ patented Red/ET recombination technology in Korea. Mbiotech was selected due to its expertise producing and marketing a wide range of molecular biology reagents.

Under the terms of the agreement, Mbiotech will be the exclusive source of recombineering kits and reagents for the Korean the biotech community.

Gary Stevens, CEO of Gene Bridges GmbH, added: “We are delighted to have reached this agreement with Mbiotech as it will give the scientific community in Korea better access to the inherent benefits of the recombineering technology”.

“Working with Gene Bridges will provide us with the opportunity to rapidly progress in the areas of biotechnology and product development,” commented Joshua Lee, the president of Mbiotech.

Mbiotech is a privately owned manufacturing and distribution company located in Seoul, Korea. The Company specialises in manufacturing a range of products including protein markers, DNA markers, Taq DNA polymerase and Nucleic Acid purification kits. Mbiotech distributes their products worldwide, using a variety of different companies and channels.

About Gene Bridges GmbH

Gene Bridges GmbH is a self-financed biotech company pioneering recombineering, the fast and precise method of engineering gene sequences. The Company was founded in 2000 as spin-off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Gene Bridges commercialises its patented recombineering technology through services, commercial licenses and kits from its facilities in Heidelberg as well as through its distributors worldwide. Further information can be found by visiting www.genebridges.com .

Further Information:

Gary Stevens
CEO, Gene Bridges GmbH
t: +49 (0)6221-13708 10
e: gary.stevens@genebridges.com

Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill Life Sciences
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com

Notes for editors:

Recombineering with Gene Bridges’ Red®/ET®

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods:

· Independent of restriction sites

· No size limits

· No unwanted mutations

· Rapid

Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs, and even E.coli chromosomes.